Abstract: The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and pain.

Abstract: A power amplifier comprising a GaN-based high electron mobility transistor (HEMT) device, wherein a power added efficiency (PAE) of the power amplifier is greater than 32% at P1 DB during operation of the power amplifier between 26.5 GHz and 30.5 GHz.

Abstract: A high electron mobility transistor (HEMT) includes a substrate comprising a first surface and a second surface on opposing sides of the substrate, a channel layer on the first surface of the substrate opposite the substrate, a barrier layer on the channel layer, a source contact comprising a first ohmic contact on an upper surface of the barrier layer, and a via extending from the second surface of the substrate to the first ohmic contact.

Abstract: An application programming interface (API) is used to migrate, from a specified source LUN to a specified target LUN, at least one specified sub-LUN data chunk, the API functioning as an interface between a storage controller and an owning application.

Abstract: An application programming interface (API), functioning as an interface between a storage controller and an owning application, is used to migrate, from a specified source LUN to a specified target LUN, at least one specified sub-LUN data chunk, the at least one specified sub-LUN data chunk having a predefined chunk size fixed by the storage controller. A specified total migration size is incrementally reduced by each completed migration of the at least one specified sub-LUN data chunk until the total migration size is zero and the migration is completed.

Abstract: A source code-based specification is implemented for use as an interface between a storage controller and an owning application to migrate a specified size of data from physical storage behind the LUN to a new physical location.

Abstract: The multiple independent processes run in an AI engine on its cloud-based platform. The multiple independent processes are configured as an independent process wrapped in its own container so that multiple instances of the same processes can run simultaneously to scale to handle one or more users to perform actions. The actions to solve AI problems can include 1) running multiple training sessions on two or more AI models at the same time, 2) creating two or more AI models at the same time, 3) running a training session on one or more AI models while creating one or more AI models at the same time, 4) deploying and using two or more trained AI models to do predictions on data from one or more data sources, 5) etc. A service handles scaling by dynamically calling in additional computing devices to load on and run additional instances of one or more of the independent processes as needed.

Abstract: Systems, apparatus, and methods are disclosed for generating a resistome profile for a subject, monitoring an infection state of one or more subjects, and/or identifying a potential infection outbreak at a facility, for example, by obtaining first data representative of at least one measure of antibiotic resistance of an organism from a first sample, identifying the organism, determining at least one of an antibiotic susceptibility phenotype, an identity of an antibiotic resistance gene, and an antibiotic to which the organism is non-susceptible, generating and comparing a first pattern to at least one known pattern to determine and generate a profile uniqueness identifier indicating a degree of similarity above a threshold between the first pattern and the at least one known pattern.

Abstract: The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment.